Market Place
Sourcing Support
OrphoMed Announces Positive Phase 2 Results for ORP-101 100 mg Once-Daily Dose
04 Jan 2022 //
BUSINESSWIRE
OrphoMed’s ORP-101 Passes Second Planned Interim Analysis in Phase 2
14 Apr 2021 //
BUSINESSWIRE
OrphoMed Passes First Interim Analysis in Phase 2 Study of Treatment for IBS-D
26 Jan 2021 //
BUSINESSWIRE
OrphoMed Resumes Recruitment for Phase 2 Adaptive Design Study of ORP-101
02 Jun 2020 //
BUSINESSWIRE
OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020
19 Feb 2020 //
BUSINESSWIRE
OrphoMed to Present Phase 1 Results of ORP-101 at Digestive Disease Week 2020
19 Feb 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.